1-10 of 10
Jonathan W. Friedberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Clinical Trials & Observations
Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile, Lode J. Swinnen, Jonathan W. Friedberg, Brad S. Kahl, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Nina Wagner-Johnston, Lakshmi Nayak, John P. Leonard, James L. Rubenstein
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3189–3199.
https://doi.org/10.1182/bloodadvances.2023011657
Published: 2024
Includes: Supplemental data
Journal Articles

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Brian T. Hill, Shuo Ma, Clive S. Zent, Andrea M. Baran, Danielle S. Wallace, Anjali Advani, Allison Winter, Jane Winter, Leo Gordan, Reem Karmali, Jane L. Liesveld, Deborah A. Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2024) 8 (2): 378–387.
https://doi.org/10.1182/bloodadvances.2023010693
Published: 2024
Journal Articles

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Clinical Trials & Observations
Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Ariela Noy, Wyndham H. Wilson, Mark Roschewski
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5320–5324.
https://doi.org/10.1182/bloodadvances.2023010223
Published: 2023
Journal Articles

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Clinical Trials & Observations
W. Richard Burack, Hongli Li, Diana Adlowitz, Janice M. Spence, Lisa M. Rimsza, Mazyar Shadman, Catherine M. Spier, Mark S. Kaminski, John P. Leonard, Michael L. Leblanc, Sonali M. Smith, Jonathan W. Friedberg
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5082–5090.
https://doi.org/10.1182/bloodadvances.2022009467
Published: 2023
Includes: Supplemental data
Journal Articles

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia

Clinical Trials & Observations
Danielle S. Wallace, Clive S. Zent, Andrea M. Baran, Patrick M. Reagan, Carla Casulo, Geoffrey Rice, Jonathan W. Friedberg, Paul M. Barr
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2496–2503.
https://doi.org/10.1182/bloodadvances.2022009382
Published: 2023
Includes: Supplemental data
Journal Articles

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis

Danny Luan, Tolulope Fatola, Ahmed Toure, Christopher R. Flowers, Brian Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad Kahl, Izidore S. Lossos, Loretta Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4413–4423.
https://doi.org/10.1182/bloodadvances.2022007687
Published: 2022
Includes: Supplemental data
Journal Articles

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

Clinical Trials & Observations
R. Andrew Harkins, Sharvil P. Patel, Michelle J. Lee, Jeffrey M. Switchenko, Stephen M. Ansell, Nancy L. Bartlett, Kristie A. Blum, Amanda F. Cashen, Carla Casulo, Jonathan W. Friedberg, Patrick B. Johnston, Brad S. Kahl, John P. Leonard, Brian K. Link, Izidore S. Lossos, Peter Martin, Matt J. Maurer, Neha Mehta-Shah, Patrick M. Reagan, Jason R. Westin, Jean L. Koff, Christopher R. Flowers
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2745–2756.
https://doi.org/10.1182/bloodadvances.2021006504
Published: 2022
Includes: Supplemental data
Journal Articles

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Clinical Trials & Observations
Juan Pablo Alderuccio, Luca Arcaini, Marcus P. Watkins, Anne W. Beaven, Geoffrey Shouse, Narendranath Epperla, Michele Spina, Alexandra Stefanovic, Jose Sandoval-Sus, Pallawi Torka, Ash B. Alpert, Adam J. Olszewski, Seo-Hyun Kim, Brian Hess, Sameh Gaballa, Sabarish Ayyappan, Jorge J. Castillo, Lisa Argnani, Timothy J. Voorhees, Raya Saba, Sayan Mullick Chowdhury, Fernando Vargas, Isildinha M. Reis, Deukwoo Kwon, Jonathan S. Alexander, Wei Zhao, Dali Edwards, Peter Martin, Emanuele Cencini, Manali Kamdar, Brian K. Link, Constantine N. Logothetis, Alex F. Herrera, Jonathan W. Friedberg, Brad S. Kahl, Stefano Luminari, Pier Luigi Zinzani, Izidore S. Lossos
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2035–2044.
https://doi.org/10.1182/bloodadvances.2021006844
Published: 2022
Journal Articles

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3132–3135.
https://doi.org/10.1182/bloodadvances.2019000526
Published: 2019
Journal Articles

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL

Clinical Trials & Observations
Monika Pilichowska, Stefania Pittaluga, Judith A. Ferry, Jessica Hemminger, Hong Chang, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, Jeremy S. Abramson, Athena Kritharis, Francisco J. Hernandez-Ilizaliturri, Izidore S. Lossos, Oliver W. Press, Timothy S. Fenske, Jonathan W. Friedberg, Julie M. Vose, Kristie A. Blum, Deepa Jagadeesh, Bruce Woda, Gaurav K. Gupta, Randy D. Gascoyne, Elaine S. Jaffe, Andrew M. Evens
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2600–2609.
https://doi.org/10.1182/bloodadvances.2017009472
Published: 2017
Includes: Supplemental data